MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Adaptive Biotechnologies Corp

Chiusa

10.38 -1.14

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.25

Massimo

10.74

Metriche Chiave

By Trading Economics

Entrata

3.9M

-30M

Vendite

5M

52M

Margine di Profitto

-56.881

Dipendenti

619

EBITDA

-3.3M

-30M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+12.95% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

600M

1.8B

Apertura precedente

11.52

Chiusura precedente

10.38

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 lug 2025, 21:01 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 20:46 UTC

Utili

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lug 2025, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 20:36 UTC

Utili

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lug 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lug 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 20:02 UTC

Discorsi di Mercato

Gold Higher to Close Out Week -- Market Talk

18 lug 2025, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lug 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lug 2025, 18:24 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lug 2025, 18:19 UTC

Utili

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lug 2025, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lug 2025, 18:11 UTC

Utili

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lug 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lug 2025, 16:29 UTC

Discorsi di Mercato

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lug 2025, 16:28 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 16:04 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lug 2025, 15:47 UTC

Discorsi di Mercato
Utili

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Confronto tra pari

Modifica del prezzo

Adaptive Biotechnologies Corp Previsione

Obiettivo di Prezzo

By TipRanks

12.95% in crescita

Previsioni per 12 mesi

Media 11.86 USD  12.95%

Alto 15 USD

Basso 9 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Adaptive Biotechnologies Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.81 / 10.18Supporto e resistenza

A breve termine

Very Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.